VAX-ID®, the heart of the Idevax company and formerly owned by Novosanis nv, is an award-winning patented drug delivery device suited for intradermal injection. The device can be preconfigured with a 32G needle as well as with a 27G needle to allow for different applications, with a penetration depth of 0.85 and 1.2mm respectively. The device is suited for accurate drug delivery of therapeutic, prophylactic and allergy drugs and vaccines in the dermal layer of the skin.
VAX-ID has several key benefits:
In light of the COVID pandemic, intradermal injection can offer a solution due to its dose-sparing potential. Studies using influenza and Hepatitis B vaccines have shown that only one fifth up to one tenth of the dose is needed to achieve a non-inferior immune response compared to the full dose administered intramuscularly or subcutaneously.